← 홈

프로그램 비교

타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일

현재 선택: 1개 · 임상 갱신 필요 1개

프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.

프로그램 선택

API CSV14행 · 1개 프로그램
OverviewToxicologyClinical

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목
CGTStandard DatabasestalePhase 2
Drugs and anti-CD19 CAR transduced T cells (Drugs and anti-CD19 CAR transduced T cells)
Shenzhen Institute for Innovation …·CD19
12 trials
Overview
Program
Drugs and anti-CD19 CAR transduced T cells
Overview
Company
Shenzhen Institute for Innovation and Translational Medicine
Overview
Modality
CGT
Overview
Target
CD19
Overview
Indication
Acute Lymphocytic Leukemia; Chronic Lymphocytic Leukemia
Overview
Phase
PHASE_2
Overview
Status
ACTIVE
Overview
Content status
Standard Database
Overview
Data Confidence
Data Confidence · Medium
Overview
Development Signal
Development Signal · Emerging
Overview
Approval status
Investigational
Toxicology
Major finding
Successful Generation of CD19 Chimeric Antigen Receptor T Cells from Patients with Advanced Systemic Lupus Erythematosus.. Although it has been shown that the production of functional chimeric antigen receptor T cells is feasible in patients with B-cell malignancies, it is currently unclear whether sufficient amounts of functional autologous CAR T cells can be generated from patients with autoimmu…
Clinical
Safety signal
Successful Generation of CD19 Chimeric Antigen Receptor T Cells from Patients with Advanced Systemic Lupus Erythematosus.. Although it has been shown that the production of functional chimeric antigen receptor T cells is feasible in patients with B-cell malignancies, it is currently unclear whether sufficient amounts of functional autologous CAR T cells can be generated from patients with autoimmu…
Clinical
Program phase
PHASE_2